论文部分内容阅读
小细胞肺癌(small cell lung cancer,SCLC)是对放、化疗极为敏感的恶性实体肿瘤之一,依托泊苷联合铂类的方案仍然是广泛期小细胞肺癌的一线标准治疗方案,客观缓解率为50%~70%。联合放化疗可以使局限期小细胞肺癌完全缓解率增加到40%~50%,但大部分患者会复发。对于复发的患者,单药托泊替康化疗是到目前为止二线治疗较为合适的治疗药物。胸部联合放、化疗、对于放疗时间和分级的优化、预防性的脑放疗可使3年生存率明显提高。
Small cell lung cancer (SCLC) is one of malignant solid tumors that is extremely sensitive to radiotherapy and chemotherapy. The combination of etoposide and platinum is still the first-line standard treatment for extensive stage small cell lung cancer. Objective response rate 50%~70%. Combined chemotherapy can increase the complete remission rate of limited-stage small cell lung cancer to 40% to 50%, but most patients will relapse. For patients with relapse, single-agent topotecan chemotherapy is by far the most suitable treatment for second-line treatment. Combined chest radiotherapy, chemotherapy, optimization of radiotherapy time and grading, and preventive brain radiotherapy can significantly improve the 3-year survival rate.